• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

COVID-19 in the absence of eosinophils: The outcome of confirmed SARS-CoV-2 infection whilst on treatment with benralizumab.

作者信息

Francis Charles H R, Hearn Andrew P, Ratnakumar Sharenja, Taylor Alexander, Duckitt Jordan, Ahmed Usmaan, Dhariwal Jaideep, Nanzer Alexandra M, Jackson David J

机构信息

Guy's Severe Asthma Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK.

School of Immunology & Microbial Sciences, King's College London, London, UK.

出版信息

Allergy. 2022 Aug;77(8):2558-2560. doi: 10.1111/all.15334. Epub 2022 May 11.

DOI:10.1111/all.15334
PMID:35491441
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9347634/
Abstract
摘要

相似文献

1
COVID-19 in the absence of eosinophils: The outcome of confirmed SARS-CoV-2 infection whilst on treatment with benralizumab.无嗜酸性粒细胞情况下的COVID-19：接受贝那利珠单抗治疗期间确诊的SARS-CoV-2感染的结果
Allergy. 2022 Aug;77(8):2558-2560. doi: 10.1111/all.15334. Epub 2022 May 11.
2
Benralizumab for severe DRESS in two COVID-19 patients.本妥昔单抗用于两名新冠肺炎患者的严重药物性皮疹伴嗜酸性粒细胞增多和系统症状（DRESS）
J Allergy Clin Immunol Pract. 2021 Jan;9(1):481-483.e2. doi: 10.1016/j.jaip.2020.09.039. Epub 2020 Oct 8.
3
COVID-19 in a severe eosinophilic asthmatic receiving benralizumab - a case study.接受贝那利珠单抗治疗的重度嗜酸性粒细胞性哮喘患者的COVID-19——病例报告
J Asthma. 2021 Sep;58(9):1270-1272. doi: 10.1080/02770903.2020.1781165. Epub 2020 Jun 18.
4
Benralizumab: A potential tailored treatment for life-threatening DRESS in the COVID-19 era.贝那利珠单抗：新冠疫情时代治疗危及生命的药物超敏反应伴嗜酸性粒细胞增多和系统症状（DRESS）的一种潜在定制疗法。
J Allergy Clin Immunol Pract. 2021 Sep;9(9):3529-3531.e1. doi: 10.1016/j.jaip.2021.06.047. Epub 2021 Jul 15.
5
Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.贝那鲁肽对痰嗜酸性粒细胞增多的哮喘患者气道嗜酸性粒细胞的影响。
J Allergy Clin Immunol. 2013 Nov;132(5):1086-1096.e5. doi: 10.1016/j.jaci.2013.05.020. Epub 2013 Jul 16.
6
Benralizumab in Real Life.倍那利珠单抗的真实应用情况
J Investig Allergol Clin Immunol. 2021 Feb 17;31(1):87-88. doi: 10.18176/jiaci.0599. Epub 2020 Jun 23.
7
Reply to "Benralizumab: A potential tailored treatment for life-threatening DRESS in the COVID-19 era".对《贝那利珠单抗：COVID-19时代治疗危及生命的药物超敏反应综合征的潜在定制疗法》的回复
J Allergy Clin Immunol Pract. 2021 Sep;9(9):3531-3532. doi: 10.1016/j.jaip.2021.06.048. Epub 2021 Jul 15.
8
Benralizumab: an anti-IL-5 receptor α monoclonal antibody in the treatment of asthma.贝那利珠单抗：一种用于治疗哮喘的抗白细胞介素-5受体α单克隆抗体。
Immunotherapy. 2018 Apr;10(5):349-359. doi: 10.2217/imt-2017-0161. Epub 2018 Jan 23.
9
Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma.抗IL-5Rα单克隆抗体贝那利珠单抗在未控制的嗜酸性粒细胞性哮喘中的疗效和安全性
Int Rev Immunol. 2016 Jul 3;35(4):294-311. doi: 10.3109/08830185.2015.1128901. Epub 2016 Apr 27.
10
Allergic bronchopulmonary aspergillosis successfully treated with benralizumab.使用贝那利珠单抗成功治疗变应性支气管肺曲霉病。
J Allergy Clin Immunol Pract. 2019 May-Jun;7(5):1633-1635. doi: 10.1016/j.jaip.2018.11.024. Epub 2018 Dec 1.

引用本文的文献

1
Severe Asthma and Active SARS-CoV-2 Infection: Insights into Biologics.重症哮喘与活动性SARS-CoV-2感染：生物制剂的见解
Biomedicines. 2025 Mar 10;13(3):674. doi: 10.3390/biomedicines13030674.
2
Eosinophil granulocytes in chronic inflammatory respiratory diseases and CRSwNP: Function, immunological basis, and clinical significance.慢性炎症性呼吸道疾病和慢性鼻窦炎伴鼻息肉中的嗜酸性粒细胞：功能、免疫基础及临床意义
Allergol Select. 2024 Mar 21;8:40-50. doi: 10.5414/ALX02469E. eCollection 2024.
3
Epidemiological and laboratory characteristics of Omicron infection in a general hospital in Guangzhou: a retrospective study.广州市某综合医院奥密克戎感染的流行病学和实验室特征：一项回顾性研究。
Front Public Health. 2023 Nov 29;11:1289668. doi: 10.3389/fpubh.2023.1289668. eCollection 2023.
4
Living without eosinophils: evidence from mouse and man.没有嗜酸性粒细胞也能存活：来自小鼠和人类的证据。
Eur Respir J. 2023 Jan 12;61(1). doi: 10.1183/13993003.01217-2022. Print 2023 Jan.

本文引用的文献

1
Asthma Phenotypes and COVID-19 Risk: A Population-based Observational Study.哮喘表型与 COVID-19 风险：基于人群的观察性研究。
Am J Respir Crit Care Med. 2022 Jan 1;205(1):36-45. doi: 10.1164/rccm.202107-1704OC.
2
Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years.患者接受 benralizumab 治疗长达 5 年的安全性和疗效综合评估。
J Allergy Clin Immunol Pract. 2021 Dec;9(12):4381-4392.e4. doi: 10.1016/j.jaip.2021.07.058. Epub 2021 Sep 4.
3
The impact of the first COVID-19 surge on severe asthma patients in the UK. Which is worse: the virus or the lockdown?英国首次新冠疫情高峰对重度哮喘患者的影响。哪个更糟糕：病毒还是封锁措施？
ERJ Open Res. 2021 Feb 1;7(1). doi: 10.1183/23120541.00768-2020. eCollection 2021 Jan.
4
Biologic treatment options for severe asthma.重度哮喘的生物治疗方案
Curr Opin Immunol. 2020 Oct;66:151-160. doi: 10.1016/j.coi.2020.10.004. Epub 2020 Nov 16.
5
Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma.贝那鲁肽在重度嗜酸性哮喘中的真实世界疗效。
Chest. 2021 Feb;159(2):496-506. doi: 10.1016/j.chest.2020.08.2083. Epub 2020 Aug 31.
6
Eosinophil responses during COVID-19 infections and coronavirus vaccination.COVID-19 感染和冠状病毒疫苗接种期间的嗜酸性粒细胞反应。
J Allergy Clin Immunol. 2020 Jul;146(1):1-7. doi: 10.1016/j.jaci.2020.04.021. Epub 2020 Apr 25.
7
Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab.重度嗜酸性粒细胞性哮喘的嗜酸性粒细胞耗竭治疗的安全性：聚焦贝那鲁肽。
Drug Saf. 2020 May;43(5):409-425. doi: 10.1007/s40264-020-00926-3.
8
Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand.嗜酸性粒细胞中Toll样受体的表达与功能：Toll样受体7配体的激活作用
J Immunol. 2003 Oct 15;171(8):3977-82. doi: 10.4049/jimmunol.171.8.3977.